TREAT TO TARGET FOR CROHN’S DISEASE WITH ADALIMUMAB TREATMENT IS COST EFFECTIVE OVER 48 WEEKS: AN ECONOMIC ASSESSMENT OF THE CALM TRIAL
Remo Panaccione 1
Jean-Frederic Colombel 2
Peter Bossuyt 3
Milan Lukas 4
Filip Baert 5
T. Vanásek 6
Ahmet Danalıoğlu 7
Gottfried Novacek
Alessandro Armuzzi
Walter Reinisch
Scott Johnson
Matthew Davis
Ezequiel Neimark
Joel Petersson
Anne M. Robinson
Roopal B Thakkar
Wan-Ju Lee
Martha Skup
1 University of Calgary,Calgary,Canada
2 Icahn School of Medicine at Mount Sinai,New York,United States of America
3 Imelda General Hospital,Bonheiden,Belgium
4 Charles University,Prague,Czech Republic
5 AZ Delta Roeselare-Menen,Menen,Belgium
6 Hepato-Gastroenterologie HK, s.r.o.,Hradec Králové,Czech Republic
7 Bezmialem Vakif University,İst
Conference
25th UEG Week 2017
Citation
United European Gastroenterology Journal 2017; 5 (Supplement 1)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]